Ganciclovir

C. diff Risk

None

Oral Bioavailability

NA

Approximate Cost

Dosing

Prophylaxis/maintenance dose: 5 mg/kg IV q24h

Treatment/induction dose: 5 mg/kg IV q12h

General Information

Common Usage

CMV infections

Drug Monitoring

CBC with differential twice weekly. Serum creatinine once weekly.

Adverse Effects

-May cause blood dyscrasias: granulocytopenia, anemia, and thrombocytopenia. Usually within first 1-2 weeks of treatment. Generally resolves within 3-7 days of discontinuation.

Pharmacology

Antimicrobial class: Antiviral, binds DNA polymerase to inhibit viral DNA synthesis.

Pregnancy category: C - animal studies have demonstrated carcinogenic and teratogenic effects.